A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Inclusion Criteria

• •Patients eligible for inclusion in this study have to fulfill all of the following criteria:
• •1. Written informed consent must be obtained before any assessment is performed.
• •2. Patients who complete the treatment epoch in study CQGE031C2201 and complete at least Visit 203 (Week 32 of the follow-up epoch, ≥16 weeks after last injection) and present with active disease as defined by UAS7 ≥12.
• •3. Patients must not have any missing eDiary entries in the 7 days prior to Visit 301 (patients are allowed to repeat until this criterion is met).
• •4. Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules.